Molecular Mechanisms Underlying Intensive Care Unit-Acquired Weakness and Sarcopenia

Skeletal muscle is a highly adaptable organ, and its amount declines under catabolic conditions such as critical illness. Aging is accompanied by a gradual loss of muscle, especially when physical activity decreases. Intensive care unit-acquired weakness is a common and highly serious neuromuscular complication in critically ill patients. It is a consequence of critical illness and is characterized by a systemic inflammatory response, leading to metabolic stress, that causes the development of multiple organ dysfunction. Muscle dysfunction is an important component of this syndrome, and the degree of catabolism corresponds to the severity of the condition. The population of critically ill is aging; thus, we face another negative effect—sarcopenia—the age-related decline of skeletal muscle mass and function. Low-grade inflammation gradually accumulates over time, inhibits proteosynthesis, worsens anabolic resistance, and increases insulin resistance. The cumulative consequence is a gradual decline in muscle recovery and muscle mass. The clinical manifestation for both of the above conditions is skeletal muscle weakness, with macromolecular damage, and a common mechanism—mitochondrial dysfunction. In this review, we compare the molecular mechanisms underlying the two types of muscle atrophy, and address questions regarding possible shared molecular mechanisms, and whether critical illness accelerates the aging process.     

The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data

This article recapitulates the evidence on the role of mammalian targets of rapamycin (mTOR) complex pathways in multiple sclerosis (MS). Key biological processes that intersect with mTOR signaling cascades include autophagy, inflammasome activation, innate (e.g., microglial) and adaptive (B and T cell) immune responses, and axonal and neuronal toxicity/degeneration. There is robust evidence that mTOR inhibitors, such as rapamycin, ameliorate the clinical course of the animal model of MS, experimental autoimmune encephalomyelitis (EAE). New, evolving data unravel mechanisms underlying the therapeutic effect on EAE, which include balance among T-effector and T-regulatory cells, and mTOR effects on myeloid cell function, polarization, and antigen presentation, with relevance to MS pathogenesis. Radiologic and preliminary clinical data from a phase 2 randomized, controlled trial of temsirolimus (a rapamycin analogue) in MS show moderate efficacy, with significant adverse effects. Large clinical trials of indirect mTOR inhibitors (metformin) in MS are lacking; however, a smaller prospective, non-randomized study shows some potentially promising radiological results in combination with ex vivo beneficial effects on immune cells that might warrant further investigation. Importantly, the study of mTOR pathway contributions to autoimmune inflammatory demyelination and multiple sclerosis illustrates the difficulties in the clinical application of animal model results. Nevertheless, it is not inconceivable that targeting metabolism in the future with cell-selective mTOR inhibitors (compared to the broad inhibitors tried to date) could be developed to improve efficacy and reduce side effects.     

Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis

For more than a decade, atherosclerosis has been one of the leading causes of death in developed countries. The issue of treatment and prevention of the disease is especially acute. Despite the huge amount of basic and clinical research, a significant number of gaps remain in our understanding of the pathogenesis of atherosclerosis, and only their closure will bring us closer to understanding the causes of the disease at the cellular and molecular levels and, accordingly, to the development of an effective treatment. One of the seemingly well-studied elements of atherogenesis is the mTOR signaling pathway. However, more and more new details are still being clarified. Therapeutic strategies associated with rapamycin have worked well in a number of different diseases, and there is every reason to believe that targeting components of the mTOR pathway may pay off in atherosclerosis as well.     

The mammalian target of rapamycin pathway and its role in molecular nutrition regulation

Mammalian target of rapamycin (mTOR) is a protein serine-threonine kinase that functions as a central element in signaling pathway involved in control of cell growth and proliferation. mTOR exists in at least two distinct multi-protein complexes, mTORC1 and mTORC2. mTOR kinase controls the translation machinery, in response to nutrients and growth factors, via activation of p70 ribosomal S6 kinase and inhibition of eukaryotic initiation factor-4E-binding protein. In this report, we review the mTOR signaling pathway and its interaction with food intake, insulin resistance, lifespan and adipogenic regulation during the molecular nutrition regulation.     

The Chemical Biology of Phosphoinositide 3‐Kinases

Since its discovery in the late 1980s, phosphoinositide 3‐kinase (PI3K), and its isoforms have arguably reached the forefront of signal transduction research. Regulation of this lipid kinase, its functions, its effectors, in short its entire signaling network, has been extensively studied. PI3K inhibitors are frequently used in biochemistry and cell biology. In addition, many pharmaceutical companies have launched drug‐discovery programs to identify modulators of PI3Ks. Despite these efforts and a fairly good knowledge of the PI3K signaling network, we still have only a rudimentary picture of the signaling dynamics of PI3K and its lipid products in space and time. It is therefore essential to create and use novel biological and chemical tools to manipulate the phosphoinositide signaling network with spatial and temporal resolution. In this review, we discuss the current and potential future tools that are available and necessary to unravel the various functions of PI3K and its isoforms.     

雷帕霉素研究进展

对雷帕霉素的免疫抑制机理及发酵、纯化、检测方法、应用等方面进行了简述，以期为雷帕霉素的研究提供参考。     

Ursolic acid,a naturally occurring triterpenoid,suppresses migration and invasion of human breast cancer cells by modulating c‐Jun N‐terminal kinase,Akt and mammalian target of rapamycin signaling

Metastasis is one of the most important factors related to breast cancer therapeutic efficacy. Ursolic acid, a naturally occurring triterpenoid, has various anticancer activities. In this study, we first observed that ursolic acid exerted a dose‐ and time‐dependent inhibitory effect on the migration and invasion of highly metastatic breast MDAMB231 cells at non‐cytotoxic concentrations. This effect was associated with reduced activities of metalloproteinase‐2 (MMP‐2) and u‐PA, which correlated with enhanced expression of tissue inhibitor of MMP‐2 and plasminogen activator inhibitor‐1, respectively. Ursolic acid suppressed the phosphorylation of Jun N‐terminal kinase, Akt and mammalian target of rapamycin, but had no effect on the phosphorylation of ERK and p38. Ursolic acid also strongly reduced the levels of NFκB p65, c‐Jun and c‐Fos proteins in the nucleus of MDAMB231 cells. A time‐dependent inhibition of the protein levels of Rho‐like GTPases, growth factor receptor‐bound protein 2, Ras and vascular endothelial growth factor in cytosol by ursolic acid treatment was also observed. In conclusion, we demonstrated that the anti‐invasive effects of ursolic acid on MDAMB231 cells might be through the inhibition of Jun N‐terminal kinase, Akt and mammalian target of rapamycin phosphorylation and a reduction of the level of NFκB protein in the nucleus, ultimately leading to downregulation of MMP‐2 and u‐PA expression. These results suggest that ursolic acid has potential as a chemopreventive agent for metastatic breast cancer.     

双歧杆菌对Treg/Th17细胞平衡及中国对虾蛋白致敏性的影响

目的通过体内实验研究婴儿双歧杆菌(Bifidobacterium infantis 13.085)和雷帕霉素对中国对虾原肌球蛋白致敏BALB/c小鼠过敏反应的治疗作用,从Treg/Th17细胞平衡及相关细胞因子角度探讨其缓解过敏的免疫调节作用机制。方法将中国对虾原肌球蛋白和弗氏佐剂混合液腹腔注射诱发BALB/c小鼠致敏,建立动物过敏模型。将实验小鼠随机分为正常对照组、致敏对照组、双歧杆菌治疗组、雷帕霉素治疗组。观察分析小鼠过敏症状,采用ELISA测定小鼠血清中特异性IgE、IgG2a的含量,采用流式细胞术测定脾脏T淋巴细胞亚群(Treg、Th17)数量,采用荧光定量PCR测定脾脏中Treg型和Th17型细胞因子和转录因子的表达量。结果第56天实验周期结束后结果发现,相比于致敏对照组,双歧杆菌和雷帕霉素治疗组小鼠过敏症状有明显的缓解,血清中特异性IgE显著降低(P0.05),脾脏Treg/Th17比值显著升高(P0.05),Th17型细胞因子IL-17A m RNA表达水平显著降低,Treg型细胞因子Foxp3 m RNA表达水平显著升高。此外,不同剂量的雷帕霉素治疗组缓解过敏反应存在剂量差异性。结论双歧杆菌13.085和雷帕霉素能有效缓解小鼠过敏症状,其作用可能通过平衡Treg/Th17细胞亚群数量,促进Treg型细胞因子表达而抑制Th17型细胞因子分泌有关。     

Grain challenge affects systemic and hepatic molecular biomarkers of inflammation,stress, and metabolic responses to a greater extent in Holstein than Jersey cows

Long-term feeding of high-grain diets to dairy cows often results in systemic inflammation characterized by alterations in acute-phase proteins and other biomarkers, both in plasma and immune-responsive tissues like the liver. The molecular and systemic changes that characterize an acute grain feeding challenge remain unclear. The current study involved 6 Holstein and 6 Jersey cows in a replicated 2 × 2 Latin square. Periods (10 d) were divided into 4 stages (S): S1, d 1 to 3, served as baseline with total mixed ration (TMR) ad libitum; S2, d 4, served as restricted feeding, with cows offered 50% of the average daily intake observed in S1; S3, d 5, a grain challenge was performed, in which cows were fed a TMR ad libitum without (CON) or with an additional pellet wheat-barley (1:1; HIG) at 20% of dry matter intake top-dressed onto the TMR; S4, d 6 to 10, served as recovery during which cows were allowed ad libitum access to the TMR. Among the 28 biomarkers analyzed in blood 12 h after grain challenge on d 5, the concentrations of fatty acids and bilirubin increased in HIG Holstein but not Jersey cows. In Holsteins, feeding HIG also increased total protein and albumin while decreasing ceruloplasmin, myeloperoxidase, and alkaline phosphatase concentrations. At the molecular level, hepatic genes associated with inflammation (IL1B, IL6, TNF, TLR4, MYD88, and NFKB1) were upregulated in Holstein cows fed HIG versus CON. Despite such response, expression of the acute-phase proteins SAA and HP in Holsteins fed HIG compared with CON was markedly downregulated. In Holsteins fed HIG versus CON, the marked downregulation of SCD, ELOVL6, and MTTP along with upregulated CPT1A, ACOX1, and APOA5 indicated alterations in fatty acid and lipoprotein metabolism during grain challenge. Genes related to ketogenesis (HMGCS2 and ACAT1) were upregulated in Jerseys, and gluconeogenic genes (PDK4 and PCK1) were upregulated in Holstein cows fed HIG, suggesting alterations in ketone body and glucose production. Expression of phosphorylated p70S6K1, RPS6, and 4EBP1 proteins, as well as total mechanistic target of rapamycin (mTOR) protein, decreased in Holsteins fed HIG, whereas phosphorylated mTOR and 4EBP1 proteins increased in Jerseys fed HIG. From a metabolic and inflammatory biomarker standpoint, data indicate that Jersey cows better tolerated the acute grain challenge. Alterations in mTOR signaling proteins in both Jerseys and Holsteins fed HIG suggest a potential role for exogenous AA in the hepatic adaptations to grain challenge. It remains to be determined if these acute responses to a grain challenge can elicit long-term liver dysfunction, which could negatively affect welfare of the cow.